Carregant...
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression
Targeting the fusion oncoprotein BCR-ABL with tyrosine kinase inhibitors has significantly affected chronic myeloid leukemia (CML) treatment, transforming the life expectancy of patients; however the risk for relapse remains, due to persistence of leukemic stem cells (LSCs). Therefore it is imperati...
Guardat en:
| Publicat a: | Blood |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Hematology
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5305055/ https://ncbi.nlm.nih.gov/pubmed/27793879 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-09-742049 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|